Drug name - Zoryve

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9907788 ARCUTIS Inhibition of crystal growth of roflumilast
Jun, 2037

(14 years from now)

US10940142 ARCUTIS Inhibition of crystal growth of roflumilast
Jun, 2037

(14 years from now)

US9884050 ARCUTIS Inhibition of crystal growth of roflumilast
Jun, 2037

(14 years from now)

US11129818 ARCUTIS Topical roflumilast formulation having improved delivery and plasma half life
Aug, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jul 29, 2025

Drugs and Companies using ROFLUMILAST ingredient

Market Authorisation Date: 29 July, 2022

Treatment: Topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. (1)

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.3% CREAM;TOPICAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.